托里帕利马布加上阿西替尼布与苏尼替尼布作为先进细胞癌的第一线治疗方法:RENOTORCH,一个随机的,开放的,第三阶段研究
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing.
与sunitinib相比,托里帕利马布加上axitinib显著改善了先进的清晰细胞癌患者的无进展生存率和整体反应率. 这种组合疗法在RENOTORCH试验中显示出可管理的安全性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 先进的清晰细胞细胞癌 (RCC) 治疗通常涉及免疫检查点抑制剂和氨酸激酶抑制剂.
- 在RENOTORCH研究中,研究了这种患者群体的新型组合疗法.
研究的目的:
- 为了比较toripalimab加上axitinib与sunitinib的疗效和安全性,作为中等/低风险高级RCC的第一线治疗.
- 评估无进展生存率 (PFS),整体反应率 (ORR),整体生存率 (OS) 和安全结果.
主要方法:
- 一项III期,随机的1:1研究,涉及421名中等/低风险不可切除或转移性RCC患者.
- 患者接受了托利帕利马布加上阿克西替尼或苏尼替尼.
- 主要终点是独立审查委员会评估的PFS;次要终点包括研究者评估的PFS,ORR,OS和安全.
主要成果:
- 托里帕利马布加上阿西替尼布显著降低了35%的疾病进展或死亡风险 (HR 0.65,P=0.0028),PFS中位数为18.0个月,相比之下,苏尼替尼布的PFS为9.8个月.
- 与sunitinib (30.8%) 相比, toripalimab加上axitinib (56.7%) 的整体应答率显著更高 (P < 0.0001).
- 观察到有利于托里帕利马布加上阿克西替尼的总生存时间的趋势 (HR 0.61).
结论:
- 与sunitinib相比,toripalimab加上axitinib在PFS和ORR方面表现出更高的疗效,用于先前未经治疗,中级/低风险的晚期RCC.
- 组合疗法呈现出可管理的安全性.
- 这些发现支持toripalimab加上axitinib作为高级RCC的新一线治疗选择.
更多相关视频
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Tumor Immunotherapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
